China Pharma Univ. GPX4 compound C18

China Pharma Univ. GPX4 compound C18: sourced facts only. name: "Overall, C18 could be a promising GPX4 covalent inhibitor to induce ferroptosis for the treatment of TNBC." [PMID:37452764]; target: "Overall, C18 could be a promising GPX4 covalent inhibitor to induce ferroptosis for the treatment of TNBC." [PMID:37452764]; developer: "Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing 210009, People's Republic of China." [PMID:37452764]; stage: "Surprisingly, C18 exhibited an outstanding potency of tumor growth inhibition in the MDA-MB-231 xenograft model with a TGI value of 81.0%@20 mg/kg without obvious toxicity." [PMID:37452764]